Market closedNon-fractional

Puma Biotechnology/PBYI

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Puma Biotechnology

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Ticker

PBYI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Los Angeles, United States

Employees

185

PBYI Metrics

BasicAdvanced
$173M
Market cap
11.32
P/E ratio
$0.32
EPS
1.30
Beta
-
Dividend rate
$173M
1.3
1.457
1.342
118.53
217.204
1.98%
8.10%
40.02%
11.318
0.753
3.41
-23.34
7.413
-3.59%
205.50%
-5.91%
-22.28%

What the Analysts think about PBYI

Analyst Ratings

Majority rating from 3 analysts.
Hold

PBYI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-10.98% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$44M
-39.39%
Net income
-$4.8M
-139.34%
Profit margin
-10.98%
-164.89%

PBYI Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 53.85%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.05
$0.12
$0.26
-$0.10
-
Expected
$0.01
$0.08
$0.30
-$0.22
-$0.10
Surprise
566.67%
56.52%
-13.24%
-53.85%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Puma Biotechnology stock?

Puma Biotechnology (PBYI) has a market cap of $173M as of July 15, 2024.

What is the P/E ratio for Puma Biotechnology stock?

The price to earnings (P/E) ratio for Puma Biotechnology (PBYI) stock is 11.32 as of July 15, 2024.

Does Puma Biotechnology stock pay dividends?

No, Puma Biotechnology (PBYI) stock does not pay dividends to its shareholders as of July 15, 2024.

When is the next Puma Biotechnology dividend payment date?

Puma Biotechnology (PBYI) stock does not pay dividends to its shareholders.

What is the beta indicator for Puma Biotechnology?

Puma Biotechnology (PBYI) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Puma Biotechnology stock

Buy or sell Puma Biotechnology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing